ClinicalTrials.gg
CompletedNCT03083704Updated Aug 8, 2023

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

A Phase 1 interventional study of Andexanet alfa (Gen 1 Process 2) and Apixaban 5 MG in Bleeding, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2017, 9 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing apixaban in Hemorrhage — 6 open to participants now, 6 under way, 3 of them phase 3. apixaban · Hemorrhage.

Enrollment
8th of 10
153 · median 2,259
Started
2017
with 2 others
Phase 1
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Portola Pharmaceuticals

Among the 10 studies testing apixaban in Hemorrhage, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1, and was the 2nd registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

6 of the 10 studies testing apixaban in Hemorrhage are open now, in 6 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing apixaban in Hemorrhage, or all of them as a file.
02

Study summary

This is a randomized, double-blind, study in healthy volunteers dosed to steady state with fXa inhibitors, designed to (1) demonstrate PK/PD comparability between andexanet manufactured by the Generation 1 and Generation 2 processes, (2) evaluate the degree to which the Generation 2 andexanet reverses fXa-inhibitor-induced anticoagulation in comparison to placebo, and (3) evaluate safety of Generation 2 andexanet.

03

Conditions studied

  • Bleeding

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be in reasonably good health as determined by the Investigator based on medical history, full physical examination (including blood pressure and pulse rate measurement), 12-lead , and clinical laboratory tests. Subjects with well-controlled, chronic, stable conditions (e.g., controlled hypertension, non-insulin dependent diabetes, osteoarthritis, hypothyroidism) may be enrolled based on the clinical judgment of the Investigator and if approved by the Medical Monitor.
  2. Must be between the ages of 18 and 75 years, inclusive, at the time of signing of the form (ICF).
  3. Agrees to have any dietary or nutritional supplements reviewed by the Investigator and potentially be withheld during the study if advised by the Investigator. Standard multivitamin and mineral supplementation will be permitted.
  4. Agrees to comply with the and reproduction restrictions of the study:

    • Men whose sexual partner is of and/or who are not monogamous must be using two acceptable methods of contraception, at least one of which must be a barrier method (e.g., spermicidal gel plus condom), for the entire duration of the study and for at least 1 month following study-drug administration; and men must refrain from attempting to father a child or donating sperm in the 1 month following the study-drug administration. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
    • Men who report surgical sterilization (e.g., bilateral vasectomy) must have had the procedure at least 6 months before study drug administration.
    • Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the case report forms (CRFs).
    • Women of childbearing potential must be using two medically acceptable methods of contraception, at least one of which must be a barrier method (e.g., non-hormone containing intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom), from the time of Screening and for the duration of the study, through at least 1 month following study drug administration. NOTE: Oral and topical hormonal contraceptive use, as well as the use of hormone-containing intra-uterine devices, is not permitted due to their increased risk of thromboembolism. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; OR
    • women must have had no regular menstrual bleeding for at least 1 year before initial dosing and either be over the age of 60 years or have an elevated plasma follicle-stimulating hormone (FSH) level (i.e., > 40 mIU/mL) at Screening; OR
    • Women who report surgical sterilization (i.e., hysterectomy, tubal ligation, and/or bilateral oophorectomy) must have had the procedure at least 6 months before study drug administration. Surgical sterilization procedures should be supported with clinical documentation and noted in the Relevant Medical History/Current Medical Conditions section of the CRF; AND
    • All female subjects must have a documented negative pregnancy test result at Screening and on Study Day 1.
  5. Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 90 mmHg at Screening and Day 1.
  6. The following laboratory values must be within the normal laboratory reference range within 28 days of Day 1: (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT); , hematocrit, and count.
  7. The following laboratory values must be equal to or below 2 times the (ULN) range within 28 days of Day 1: (AST)/alanine aminotransferase (ALT) and total .
  8. The Screening serum creatinine must be below 1.5 mg/dL within 28 days of Day 1.
  9. between 19-30 kg/m2, inclusive, and body weight at least 50 kg.
  10. Agrees to abstain from alcohol consumption for the duration of the domicile period, and from the use of drugs of abuse for the duration of the study.
  11. Able to read and give written informed consent and has signed a consent form approved by the Investigator's Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

Exclusion criteria

Exclusion Criteria:

  1. Previous use of andexanet or previous participation in the current study.
  2. History of abnormal bleeding, signs or symptoms of active bleeding, or risk factors for bleeding.
  3. Has a stool specimen that was positive for occult blood within 6 months of study Screening or during the Screening Period.
  4. Past or current medical history of thrombosis, any sign or symptom that suggests an increased risk of a systemic thrombotic condition or thrombotic event, or recent events that may increase risk of thrombosis.

    a. For example, subjects with a known or suspected hypercoagulable state, history of VTE, DVT, stroke, myocardial infarction [MI], cancer [other than non-melanoma skin cancer], atrial fibrillation, heart failure, cardiomyopathy, phlebitis, lower extremity edema, major surgery or trauma within 2 months of Study Day 1, airplane travel ≥ 2 hours during the 4 weeks prior to Study Day 1, or general immobility are excluded.

  5. Absolute or relative to anticoagulation or treatment with apixaban, rivaroxaban, enoxaparin, or edoxaban.
  6. Prior consumption of (by any route) one or more doses of aspirin (including baby aspirin), salicylate or subsalicylate, other antiplatelet drugs (e.g., ticlopidine, clopidogrel), non-steroidal anti-inflammatory drugs, fibrinolytic, or any anticoagulant within 7 days prior to Day 1 or is anticipated to require such drugs during the study.
  7. Receipt of (by any route) hormonal , hormone replacement therapy (HRT) (including over-the-counter products), or testosterone during the 4 weeks prior to Study Day 1 or is anticipated to require such drugs during the study.
  8. Family history of or risk factors for a hypercoagulable or thrombotic condition, including one of the following:

    1. Factor V Leiden carrier or homozygote.
    2. Protein C, S, or ATIII activity below the normal range.
  9. History of adult asthma or or current regular or as-needed use of inhaled medications.
  10. Active , , or -1/2 infection
  11. Use of any drugs that are strong dual inhibitors or inducers of and P-gp within 7 days prior to Study Day 1 or anticipated need for such drugs during the study.
  12. Participation in an drug study within 28 days of Day 1 or Day 1 is within 5 half-lives of the investigational compound.
  13. Positive screen for drugs of abuse at Day 1 that is not explained by a prescription medication that the subject is known to be taking.
  14. A medical or surgical condition that may impair drug (fXa inhibitor or andexanet) metabolism.
  15. Allergy to any of the vehicle ingredients: tris, arginine, sucrose, hydrochloric acid, mannitol, and polysorbate 80.
  16. Current breastfeeding or a positive pregnancy test at Screening or Day 1.
  17. Any condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would in the opinion of the Investigator increase the risk of the subject's participation in the study. This would include but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
  18. The subject is not judged by the study staff to have adequate bilateral venous access.
  19. Unwillingness to adhere to the activity requirements of the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: Apixaban 5 MG · Biological: Andexanet alfa (Gen 1 Process 3)

  • Experimental
    Cohort 2

    Drug: Rivaroxaban 20 MG · Biological: Andexanet alfa (Gen 1 Process 3)

  • Experimental
    Cohort 3

    Biological: Andexanet alfa (Gen 1 Process 2) · Drug: Apixaban 5 MG

  • Experimental
    Cohort 4

    Drug: Apixaban 5 MG · Biological: Andexanet alfa (Gen 2)

  • Experimental
    Cohort 5

    Drug: Rivaroxaban 20 MG · Biological: Andexanet alfa (Gen 2)

  • Experimental
    Cohort 6

    Drug: Enoxaparin sodium · Biological: Andexanet alfa (Gen 2)

  • Experimental
    Cohort 7

    Drug: Edoxaban 60 MG · Biological: Andexanet alfa (Gen 2)

  • Experimental
    Cohort 8

    Biological: Andexanet alfa (Gen 2) · Drug: Apixaban 10 MG

  • Experimental
    Cohort 9

    Biological: Andexanet alfa (Gen 2) · Drug: Rivaroxaban 10 MG

  • Experimental
    Cohort 10

    Drug: Enoxaparin sodium · Biological: Andexanet alfa (Gen 2)

  • Experimental
    Cohort 11

    Drug: Edoxaban 60 MG · Biological: Andexanet alfa (Gen 2)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by AUC(0-∞)

    Time frame: Day 1 through Day 7

  2. Reversal

    To evaluate reversal of fXa-inhibitor-mediated anticoagulation, as measured by anti-fXa activity

    Time frame: Day 1 through Day 7

  3. Safety will be evaluated by assessment of adverse events, venous thromboembolic events, physical exam findings, vital signs, oxygen saturation, fecal occult blood testing, and 12-lead ECGs.

    Non-laboratory-based Endpoints

    Time frame: Day 1 through Day 32

  4. Safety will be evaluated by analyzing the following: • Hematology, chemistry & urinalysis.

    Laboratory-based Endpoints

    Time frame: Day 1 through Day 32

  5. Safety will be evaluated by analyzing the following: • Antibodies to andexanet, fX, & fXa, and neutralizing antibodies

    Laboratory-based Endpoints

    Time frame: Day 1 through Day 32

  6. Safety will be evaluated by analyzing the following: • TFPI, D-dimer, F1+2, thrombin-antithrombin III, and Russell's viper venom time

    Laboratory-based Endpoints

    Time frame: Day 1 through Day 32

  7. Safety will be evaluated by analyzing the following: fX, fibrinogen, tissue-type plasminogen activator, plasmin-alpha2-antiplasmin complexes, thrombin activatable fibrinolysis inhibitor, beta-thromboglobulin, platelet factor 4 & soluble thrombomodulin

    Laboratory-based Endpoints

    Time frame: Day 1 through Day 32

Secondary outcomes

  1. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: Total area under the plasma concentration-time curve from time 0 to infinity (AUC(0 ∞)

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  2. Reversal

    To evaluate reversal of fXa-inhibitor-mediated anticoagulation, as measured by free fraction of the fXa inhibitor

    Time frame: Day 1 through Day 7

  3. Reversal

    To evaluate reversal of fXa-inhibitor-mediated anticoagulation, as measured by restoration of thrombin generation

    Time frame: Day 1 through Day 7

  4. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: Cmax - Maximum Observed Concentration

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  5. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: Tmax - Time to maximum observed plasma concentration (Tmax)

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  6. To evaluate pharmacokinetics of Generation 2 process andexanet as measured by following PK parameter: t1/2 - Plasma t½, determined by linear regression of the log concentration on the distribution & terminal portion of the plasma concentration-time curve

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  7. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: CL - Clearance

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  8. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: Vss - Volume of distribution at steady state (Vss)

    Pharmacokinetics

    Time frame: Day 1 through Day 7

  9. To evaluate the pharmacokinetics of Generation 2 process andexanet, as measured by the following PK parameter: lamda z - The terminal or elimination rate constant (lamda z)

    Pharmacokinetics

    Time frame: Day 1 through Day 7

07

Study locations

1 site
  • West Coast Clinical Trials
    Cypress, California 90630, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Sep 2017, 7 months.

Of 17 phase 1 interventional studies under Hemorrhage, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 42. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2017
First posted
Mar 20, 2017
StartActual
Feb 26, 2017
Primary completionActual
Sep 28, 2017
CompletionActual
Sep 28, 2017
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03083704
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Feb 26, 2017
Primary completion
Sep 28, 2017
Completion
Sep 28, 2017
Last update
Aug 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PRT064445 · Apixaban · Rivaroxaban

Start the discussion